Clinical Trials Logo

Filter by:
NCT ID: NCT06341192 Not yet recruiting - Clinical trials for Anterior Cruciate Ligament Injuries

Comparison Between Combined ALLR With Single Bundle and Double Bundle Anterior Cruciate Ligament Reconstruction

ALLR
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test and compare different surgical techniques in patients with anterior cruciate ligament (ACL) injuries. The main questions it aims to answer are: - What are the optimal criteria for selecting between single-bundle ACL reconstruction combined with anterolateral ligament (ALL) reconstruction versus double-bundle ACL reconstruction combined with ALL reconstruction? - How do these two surgical techniques compare in terms of post-operative knee stability, functional outcomes, and reducing re-tear rates? Participants will: - Undergo pre-operative MRI imaging, ligament stability testing, and motion analysis evaluations - Be randomly assigned to either: - Single-bundle ACL + ALL reconstruction - Double-bundle ACL + ALL reconstruction - Receive the assigned surgical procedure - Participate in post-operative follow-ups, ligament stability testing, and motion analysis at 6 months and 1 year Researchers will compare the single-bundle ACL + ALL group and the double-bundle ACL + ALL group to see if one technique demonstrates superior knee stability, functional outcomes (e.g. return to sport ability), and lower ACL re-tear rates.

NCT ID: NCT06339645 Not yet recruiting - Clinical trials for Safety and Effectiveness Between Intravesical Platelet-rich Plasma Injection in Patients With Interstitial Cystitis/Bladder

Intravesical Platelet-rich Plasma Injection in Patients With Interstitial Cystitis/Bladder-A Retrospective Study

Start date: April 1, 2024
Phase:
Study type: Observational

The correlation of safety and effectiveness between intravesical platelet-rich plasma injection in patients with interstitial cystitis/bladder-A retrospective study to evaluate the correlation of safety and effectiveness between intravesical platelet-rich plasma injection of IC/BPS, with age of at least 20-84 years old in Taiwan of either sex with IC/BPS symptoms and proven of IC by cystoscopic hydrodistention. Patients who meet all eligibility requirements for entry into the study of intravesical PRP injection.

NCT ID: NCT06339424 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma

PhotonAB
Start date: March 29, 2024
Phase: Phase 2
Study type: Interventional

Atezolizumab (anti-programmed death-ligand 1; anti-PD-L1) in conjunction with bevacizumab (anti-vascular endothelial growth factor; anti-VEGF) has become the established standard first-line systemic treatment for unresectable hepatocellular carcinoma (HCC). Despite an improved objective response rate (ORR) of 27%, the majority of patients face HCC progression and liver failure [Finn et al., N Engl J Med 2020]. Developing a new combined treatment strategy to overcome resistance to anti-PD-L1 and anti-VEGF is essential to improve patient outcomes. Radiation treatment (RT) is highly efficacious in controlling localized solid tumors and has become an integral component of the treatment algorithm for unresectable HCC. Importantly, a recent retrospective cohort described that RT combined with atezolizumab plus bevacizumab was associated with favorable median overall survival of 16.1 months (Manzar et al, Cancers 2022). Our preclinical study (Hsieh et al., Science Immunology 2022) revealed that RT combined with PD-L1/PD-1 blockade induces immunogenic cell death and tumor antigen cross-presentation in antigen-presenting cells, thereby potentiating the systemic antitumor T cell responses in murine tumor models. However, whether the combinatorial therapy with RT, atezolizumab, and bevacizumab can trigger synergistic antitumor effects and systemic immune mobilization has not yet been validated in clinical trials for unresectable HCC. Both atezolizumab/bevacizumab and X-ray RT are approved treatment methods for unresectable HCC by the U.S. and Taiwan Food and Drug Administration (FDA). The present phase II non-randomized trial aims to prospectively document the therapeutic efficacy, safety, and immunological responses in patients with unresectable HCC treated with atezolizumab/bevacizumab combined with conventional photon radiotherapy.

NCT ID: NCT06334237 Not yet recruiting - Migraine Clinical Trials

Psychosomatic Factors Influencing the Efficacy of Holistic Care for Migraine

Start date: April 15, 2024
Phase:
Study type: Observational

This research project aims at exploring the psychosomatic factors that influence and moderate the efficacy of holistic care and personalized treatment for migraine patients. It is a prospective longitudinal observational study. The project's goal is to understand how physical, psychological, spiritual, and social factors affect the care and treatment outcomes for migraineurs. The study will include participants aged 18 to 65, who meet the International Headache Society's criteria for migraines. It will utilize a range of methodologies including questionnaires, interviews, and medical records to collect data on various factors like lifestyle, psychological state, and social support. The project will assess the effectiveness of treatments, compliance, and other outcomes such as emotional and sleep conditions.

NCT ID: NCT06331663 Not yet recruiting - Pain, Procedural Clinical Trials

SPI and Remifentanil in Skull Pin Fixation

Start date: April 1, 2024
Phase: Phase 4
Study type: Interventional

Forty patients were enrolled, and all patients used total intravenous anesthesia (remifentanil-propofol based total intravenous analgesia) as anesthesia induction and maintenance. According to the preliminary data of this department, patients who underwent intracranial surgery for skull pin fixation used remifentanil 5.0-6.0 ng/ml, while the hemodynamics is relatively stable. Therefore, when this plan is implemented, the patient needs to be under the same depth of anesthesia (monitored by electroencephalography, maintaining a value of 40-60), first start with remifentanil 5.0 ng/ml, and use the up and down method as adjust 0.5 ng/ml of concentration of remifentanil each time. Inadequate antinociception (Surgical Pleth Index(SPI) > 80 and hyperdynamics (the increased heart rate (HR) and mean blood pressure (MBP) above 20% of baseline or HR>100bpm and arterial blood pressure(ABP)>180/100mmHg)) is defined as failure, therefore we increase remifentanil by 0.5 ng/ml; otherwise, the setting is considered successful without abovementioned situations. Data collection: heart rate, mean blood pressure, Surgical Pleth Index, bispectral Index, pulse pressure variance, systolic pressure variance, concentrations of propofol and remifentanil before 2 mins, during, 5, and 15 mins of skull pin fixation were recorded and analyzed.

NCT ID: NCT06322810 Not yet recruiting - Analgesia Clinical Trials

ESP Versus PIFB for Analgesia in Open Cardiac Surgery: a Randomized Control Trial

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

This clinical trial compares analgesia efficiency and recovery outcomes between two different fascial plane block techniques (ESPB vs.PIFB) in cardiac surgery patients participant population/health conditions]. The main questions it aims to answer are: - Does ESPB provide superior analgesia than PIFB - Do patients who receive ESPB have better recovery outcomes

NCT ID: NCT06318468 Not yet recruiting - Competence Clinical Trials

The Effectiveness of Various Teaching Methods to Enhance the Comprehensive Nursing Assessment Skills of New Nurses

Start date: April 2024
Phase: N/A
Study type: Interventional

This study is going to compare different teaching strategies for improving newly recruited nurses' comprehensive nursing assessment skills.

NCT ID: NCT06317792 Not yet recruiting - Clinical trials for Parkinsonism in Diseases Classified Elsewhere

The Efficacy of Online Exergaming-Integrated Physiotherapy for Parkinson's Disease

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

To validate the efficiency of online exergaming-based physiotherapy. We will enroll patients with Parkinson's disease in postural instability and gait disturbance motor phenotype in the study and divide them into two groups in a randomized controlled study.

NCT ID: NCT06317584 Not yet recruiting - Diabetes Clinical Trials

Empowerment-based Complementary and Alternative Medicine (ECAM)

CAM
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

This phase study will use a randomized trial method to evaluate the performance of the ECAM educational app in the promotion of CAM health literacy and communication among patients with diabetes.

NCT ID: NCT06315374 Not yet recruiting - Clinical trials for Chronic Pulmonary Disease

3D-Printed Aerosolized Medication Delivery Assist Device in Patients With Chronic Respiratory Diseases

Start date: March 30, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the auxiliary benefits of three-dimensional printed activating assistive devices for soft-mist inhaler on patients' utilization habit.